Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation

Reuters

2025/09/03

<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation

Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564339566"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564339566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564339566?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564339566","market":"nz","top_or_hot":-1,"title":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-03 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTB","symbol_name":"康乃德生物医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL4TYCX0:1","article_id":"2564339566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564339566","pubTimestamp":1756903217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha  treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTB":"康乃德生物医药","BK4139":"生物科技"},"translate_title":"Connect Biopharma在最新演示中展示了Rademikibart在哮喘和COPD治疗方面的巨大潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9},"content_text":"Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation\n    \n\n        Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}